You are here

Industry News

Advamed Smart Brief

July 13, 2018
An agreement has been reached by Germany-based Gerresheimer to pay up to $409 million, which includes milestone-based payment -More
July 13, 2018
A round of Series B financing has brought in $11.87 million for Wayne, Pa.-based angioplasty balloon developer Cagent Vascula -More
July 13, 2018
An offering of about 2.2 million shares of common stock has been priced by Redwood City, Calif.-based Avinger in hopes of rai -More
July 13, 2018
A round of Series B financing has been closed by San Jose, Calif.-based Venclose, which intends to use the proceeds to develo -More
July 13, 2018
A new Current Procedural Terminology code has been approved for CathWorks' 3D FFRangio noninvasive fractional flow reserve an -More
July 13, 2018
The Centric-T Pedicle-Based Retractor System has been released by Life Spine as part of its Centric Access Portfolio.  -More
July 13, 2018
AdvaMed supports the objective of draft guidance issued by the FDA's Center for Devices and Radiological Health to expand the -More
July 13, 2018
The FDA has given Medtronic expanded labeling for its SelectSecure MRI SureScan model 3830 cardiac pacing leads for use in Hi -More
July 13, 2018
Abbott has obtained approval from the FDA for the third generation of its MitraClip system for use in transcatheter-based mit -More

Industry News

Stat News
If your health care is covered by Medicare, like more than 55 million of your fellow Americans, where you live partly determines what Medicare will pay for. The process for deciding what items and services are covered from region to region needs reform.
PR Newswire
SAN ANTONIO, TX., May 23, 2018 - CeloNova BioSciences, Inc. (CeloNova), a global medical device company that offers a family of innovative products based upon its proprietary Polyzene™-F nanocoating technology, today announced 1-year clinical trial results from the eCOBRA post-market study of the company's COBRA PzF™ NanoCoated Coronary Stent (NCS) System. The clinical trial results demonstrated 4.3% target lesion revascularization, 0.3% late stent thrombosis and 8.6% major adverse...
Helius Medical Technologies, Inc.
NEWTOWN, PA.,  April 11, 2018 - Helius Medical Technologies, Inc. (“Helius” or the “Company”) today announced the pricing of an underwritten public offering of 2,141,900 shares of its Class A common stock and warrants to purchase 2,141,900 shares of its Class A common stock at a public offering price of US$7.47 per share and accompanying warrant, before underwriting discounts and commissions.  The net proceeds to the Company from this offering, after deducting the underwriting discounts,...
PR Newswire
California-based Myoscience, Inc. announced today that it received 510k clearance from the US FDA for Smart Tip with Nerve Stim, the latest innovative tip for Myoscience’s iovera° platform technology. With the FDA clearance for Smart Tip with Nerve Stim, physicians will be able to stimulate a nerve in advance of delivering iovera° cold therapy to the treatment area, reducing patient treatment times. Additionally, the use of Smart Tip with Nerve Stim enables physicians using iovera° to access...
Media Planet
It sometimes strikes without warning. People of any age, race, ethnicity and gender are at risk. In fact, it is the leading killer of both men and women in America. It is heart disease, and each year it claims the lives of over 600,000 Americans, accounting for one-quarter of all deaths in the United States.